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ABSTRACT
The overall objective of this dissertation was to provide greater insight into 
changes in vascular function, blood flow regulation, and exercise-induced hyperemia 
associated with health, chronic heart failure (CHF), and heart transplantation (HTx).  In 
the first study, we aimed to determine the central and peripheral contributions to 
movement-induced hyperemia in response to passive movement by comparing humans 
with a denervated heart (HTx) to intact controls.  We observed a four-fold reduction in 
the transient increase in femoral blood volume entering the leg in response to passive 
limb movement in the HTx recipients compared to controls. These findings highlight the 
key role of the reflex increases in heart rate (HR) and the associated rise in cardiac output 
(CO) response as an important mechanism which contributes to movement-induced 
hyperemia in humans.  The second study investigated the changes in vascular function 
and the role of oxidative stress from health to CHF, HTx, and beyond.  Utilizing flow-
mediated vasodilation (FMD) we documented reduced vasodilatory capacity in CHF 
patients, which was normalized in early HTx recipients, and then an eventual decline in 
vascular function in the HTx recipients that were the furthest time from transplantation 
(>14 yrs post-HTx).  The acute ingestion of the antioxidant cocktail (AOC) was able to 
significantly increase FMD by 55% in these >14 yrs post-HTx recipients suggesting that 
free radicals, and the associated decrease in nitric oxide bioavailability, are largely 
responsible for their endothelial dysfunction.  The third study sought to better 
characterize the role of free radicals in regulating central and peripheral hemodynamics at 
rest and during exercise in patients with CHF using an oral AOC and dynamic handgrip 
exercise.  The ingestion of the AOC had significant systemic hemodynamic effects which 
were only evident in the patients with CHF.  Specifically, the AOC further reduced the 
patients already lower MAP (~5%), increased CO (~10%), and caused a fall in systemic 
vascular resistance (~12%). These data imply that systemic vascular resistance appears, at 
least in part, to be free radically-mediated.  Collectively, this research has provided 
significant insight into the cardiovascular consequences of CHF and HTx in terms of 
oxidative stress, vascular function and hemodynamic regulation. 
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2Chronic heart failure (CHF) is a major cause of morbidity and mortality in the 
United States and according to the American Heart Association (AHA) is the leading 
cause of hospitalization among those individuals on Medicare (11). The AHA also 
estimates that more than 5 million people in the United States have CHF, with 550,000 
new cases being diagnosed each year.  CHF is a disease that has many different origins 
and is typically the most severe manifestation of almost every form of cardiac disease, 
including myocardial infarction, coronary atherosclerosis, hypertension, congenital heart 
disease, and cardiomyopathies.
The underlying physiology of CHF is the inability of the heart to fill or pump 
blood efficiently, compromising systemic perfusion, increasing sympathetic nerve 
activity, and limiting physical function. CHF most often effects older individuals that 
have one or more of the following risk factors: high blood pressure, coronary artery 
disease, myocardial infarction, irregular heartbeats, diabetes, congenital heart defects, 
sleep apnea, certain viruses, alcohol use, or some kidney conditions.  There is no cure for 
CHF and in the most severe stage of this disease process; heart transplantation (HTx) is 
usually the best option.
In recent decades heart transplantation has advanced from an experimental 
procedure to an accepted life-extending therapy for patients with the most advanced 
stages of heart failure. The health and elasticity of major arteries is a risk factor for 
various types of cardiovascular disease (4) and has also been suggested to “naturally” 
deteriorate with age (12). Therefore, as quality of life and survival rates continue to 
climb for HTx patients, there is greater interest in understanding the long term effects of 
3HTx and the associated pharmacological therapy, particularly in the areas of vascular 
function and blood flow regulation.
HTx not only removes the failing organ but also results in denervation of the
heart, which means there is no longer direct parasympathetic or sympathetic cardiac 
control.  Additionally, many of these patients had a chronic debilitating cardiac illness 
preoperatively, resulting in many detrimental physiological changes. Vascular 
dysfunction and blood flow dysregulation have been documented in patients with CHF 
(9), resulting from the inability of vessels to respond to physiological stimuli such as 
shear stress (6) and augmented sympathetic nerve activity (5). Thus, the ability to 
respond and adapt to changing stimuli, such as exercise, may be very different in both 
CHF patients and HTx recipients compared to healthy individuals.  
The understanding and monitoring of vascular function is important as it relates to 
the prevalence of cardiovascular disease (7) and is even more germane in patients with 
CHF and following HTx. Additionally, in light of the increasing interest in isolating the 
physiological and mechanical contributors to the blood flow response, especially during 
exercise (exercise hyperemia) (16), the abnormal hemodynamic responses common in 
CHF and HTx patients may help to further explain the mechanisms responsible for vessel 
vasodilation and exercise hyperemia in both health and disease.
Oxidative stress is caused by an imbalance between free radical production and 
antioxidant capacity. High levels of free radicals have been associated with many chronic 
diseases including hypertension, atherosclerosis, diabetes, and the normal aging process 
(17), but this is especially true for CHF (1, 8).  In CHF patients, elevated free radicals 
have been linked to impaired endothelial-dependent vasodilation (13, 14) and exaggerated 
4sympathetic nerve activity particularly with exercise (10, 15). In HTx recipients, the 
development of high levels of oxidative stress has also been associated with endothelial 
dysfunction (2) and the development of cardiac transplant-associated arteriosclerosis (3).
This, coupled with the highly invasive nature of heart transplantation and the effects of 
previous cardiac illness, lends itself to the idea that antioxidant therapy may decrease 
circulating levels of free radicals and may actually improve vascular function and blood 
flow regulation in HTx recipients.
Accordingly, vascular function, blood flow regulation, and exercise-induced 
hyperemia will be examined in healthy controls, CHF patients, and HTx recipients with 
varied time since surgery with and without oral antioxidant supplementation.
Specifically, the first study will utilize HTx as a denervated model to better understand 
the central and peripheral contributions to exercise-induced hyperemia.  The second study 
will take a more clinically relevant approach comparing vascular function, assessed by 
flow-mediated vasodilation (FMD) and reactive hyperemia (RH) with and without the 
supplementation of an antioxidant cocktail in healthy controls, CHF patients, and HTx 
recipients.  The third study will determine the role of oxidative stress in the central and 
peripheral responses to handgrip exercise for healthy controls and patients with CHF.  
The overall objective of this dissertation will be to provide greater insight into changes in 
vascular function, blood flow regulation, and exercise-induced hyperemia associated with 
health, CHF, and HTx.
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CHAPTER 2
UNDERSTANDING EXERCISE-INDUCED HYPEREMIA: CENTRAL AND 
PERIPHERAL HEMODYNAMIC RESPONSES TO PASSIVE LIMB MOVEMENT IN 
HEART TRANSPLANT RECIPIENTS
Reprinted with permission from
Hayman, MA, Nativi, JN, Stehlik, J, McDaniel, J, Fjeldstad, AS, Ives, SJ, Wray, DW, 
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,1111 l~ on lbi/ JWSi'" I., aDd !nl\o~d K> 250 nmfls .• limin'lin, 
blood ftow lO) lbi/ I"" .. , It, lOr !lie onti ... 3 min. Tlis .. ·as done to 
.limin ... ftoo!llU!!ono in blood now 10 III< I""· ... It, as' COrt\O'I .... .-
01 chansi"ll V""i!Orionli and ~mrifugol for~ "" !lie 1000· ... It, 
Urw"r>ool 111< ,,,,,,·.,,,,,nL 1",~01 pilO! work ,., .. :tIed ~ nilluW .1f.<1 
<I ci,Io., tuffi.", or not ""ffi.n, til< "",trolle, in !hi: oanr ",a,,,,,,, 
Tb:rdort. a kM .. , 10, ""If 00 tho C<Xltrolle, "-' DOl oppIied ;n tIi. 
>ludy I'lusi,~ .""ci .. "-' :odlioo.~d by • ""'mt>:< cl II., .. scarrh 
.. am """0, It.. oub}t<"!·. [0,. . .,. It, 'hrougll • f2ngC of moboo. 
... ftned by 90" .Dd I b~ ;0,11 onaI<t.. ., • ra" o r I H~ 
(IhrQuSOOU! "'" protoCOl. III< con!rol 1o, .. <03i1lt<l r.llyo~lODdtd and 
.. pporltd). Rt3I·11me fH<lr>ct 10 !hi: iD"'<liiOlOl'''-, prm; ... d by I 
po.lIl~oo .. ,...,. ' 0 ..... ~ • .,.,......01 rq~ of 1IIOIi<Xl. aDd. mrlJOo 
~ __ .. d '" 1I>ll1llllin Iho C"MIeOlOl!. Ikf«< III< lWIand _gil. 
"", !lie I'fOI'X<lI, til< .. bjoods ""ff< _nged 10 ... lIiIIu ~,~ :wd 
"No.t ID)' ..... 10 -..I .,!It 10K """...,...,Qi. To .Y()Od I $Iaotk ... Ik .. 
mol ........ ,(JUUnOe 10'" pow; ... """"" .... m.th< "b;«11 .. = mn 
.... "lft d>ao p;wi'" ,00\'(11):111 .. wId ~ .,._ ....... 10 miDiInize Iho 
dJanDo 0I:an :InUci .. t.lO')' ~ • ...,. ........ oot. .nl<Iomod 01 uXlly 
"'hm tint mo'l'rnmt .. wid il0b'" 
MI.riN bloodflow ~M blood '''''00'' ......... u""'""J OM IiIUI):otJ. 
,\I< ...... m ...... of .".d.1 blood ""o<'ty .Dd ....... , diamolft " ...... 
prtkJrmI<I;n bOlb tho tnctrilllonery fta--·""",,lI<d <lil'bOll (Ro1D) 
and pua'" .""oi .. proIocoi ... ilh Losie 7.,od Lope. ultraSOaOd 
sy""",, (o,,,,.r:oI ~loroio Mtd!~ S)"OIems. M,I""u~"'. WI), T ... 
1..01>0 7 and LOll. e.' ... equlppod .. ';(h H ..... :Ir ... ray tr"""'""", 
raWlg"' on "lUging freq ... ncy of 14.00 12 MHz. rtsptCtively_ 
Vo",,1 dion",", " ... do .. nni""d .1. pt"!pt"(ICIi"tlar '051< alooog til< 
""",,tral w, of II", ocom<d .... , Blood .d<><ily " 'as obIa;""d wiug ~'" 
"",., ''''''"00''''' wi(h • Dewlor f",qomoy of 5 MHz. All blood 
,'dooi(y ",.:uu .. ",.nts "' ... obtain.d w;lh tbt probo 'pprOpr;'ldy 
)l<lSi(;onot1I0 "tailllOln an (I'"ona(ioo .. '''~ or l'iO" Of I ..... n" sample 
vol."", ... as """iniud ~<Ii"i (0 ,,,,",,,,,1 aiJ,t .00 ..... ,,",,""',ed 
"!lmn Ih" "01.11<1 b.uod OIl rt~I·li~ ullr.uooOO 'i.ll.1li .. ~OlL ArIo<riai 
di ..... !t' was " .. u~~ .. Id II"'" "olooily (V __ l .. ," .. longk· 
""""",,,d.nd , .... nliily· ... ciVllo!<l ""'. U( .... , !Ito <1h"~ (AUC)J " ...... 
~"'O 1Il1Ol, .. 6o:dly 001""1.",,, ."'"1 roollnem:o.lly .vail~bIe sor",,.,. 
(LOCi'" .,><1 Losio e~ U"Di lI' .. rioi di"""'lt.:meI V __ .!lIe blood 
n"", in !lie In<lial and "'moral Iflt ........... ~C\lt.1td Sol foUCI"'f: 
9100<1 _ V _ _ "'. __ I di ...... lefl2)" 60, "'horn blood n"",· io 
io miIliLl<B pt", ""D~" 
f~-"'Itd dilolil'JOO. II.I .. ,,~ and abIoI.", RotD ....... ~.:u. 
111«1 .. I!.. pt"oa:Dl d ...... and 1ht: at.>t.", .1, "'8p<ro.-dy. fH)nl 
tnlin' .... ry di ....... ' (0 the l .. cnI <Ii;lrllflef tldlie • ..., dori", tbi: 120 
I of poe!inlatiou ,mall"'" All .llnOOUOO ' ..... 1 lonleQ <Ii .......... 
!IK3M1mIC ..... .. t'IC t''oIull«l don'. ('Dd <Ii ... &- (ro"."I'"",II"I to 
"" R "",ve docomoC1l<'d by !he ..... 1111_ ECG "pall (Loci<" 7~ 
AD orAI)"" or III< di:lllllt .... " ... ~komtd "';n, otf·lint atIIOIDOIio 
N"~OO 9n1d1u11 Anal) .... , oo/tIIo_ (MMioal lmapn, AppIi . 
.. liono, ConhiUo, IAI,.hirlt;. dntrnbod U1 ..... 1 .1", ... "",,, (3:b). 
.$lI ...... ,~u ~1Id ftQ€f"", ~u_ ",/aoIa~ Sho .. .- is 
boboot<! 10 bo "'" m.clwum wllb ... b .... tho .,...,., .. "t>do.:>Ihelimm 
and _111'0 oubtc"q.lcnl ''UOdibtiao (7~ S""'" blood """""'ty ..... 
DOl m:.....-N, $I ......... III .... 'P ...... ropI< "' .... rt (-'. 36) ..... 
caI<'Il121<d .. i", lit. f<lll"",i",,,,,,aaoo: 51", .. ""'" (in 1_') - S·V __ 
(in <,,,tI.)lveIO<l <It ....... , (in cm~ c.m.I.liw ",llC!ive h)'!>-.,.,ria 
(RII ) (AUC) ~ ..... ff ",lux (lOll! ~ood ftOOl 0'", 2 min) ,,~ 
In .. ...... d ull", IIIc lnpt"roidai ",Ie and caI.:ublOd 1$ fol!(1O."t.: 
I (Ytl',. . x,) -+- (112)()\., ),:)(.1' .. , - z,)I. To oormaliu til< 
.....ooi1.aOlI for.tot .. <W. I'M!) "':lldividod by tho """,III.Ii", <bu, 
..... ('loM""lIIll"rlJ ' . ) (J1), 
Tahl" 2. CharaCl<!rislicl P<lrI;"'l1~ 10 Ihe IITx 
ff!dp;f!I" group 
• 0.._. (_.:10 ..... , .... _~Iq) 
Di.oI ..... (00<1>0_ • ......"o,.lty) 
T ... ,... IIT",.-hI • $Ii R<.l«'- ~pooo4o<o L<a _.w.;..rn .. f..., ..... 'lIo 
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Crlllmi ""riabl ... IIR. SV, CO,.Dd mo.o .((en>l pre ...... (MAP) 
"'C'" <rlermioed ,,;111 a M""""ter (lin'.,.... Me<lCll S) .... ms, Am, 
OIerd:lm, Tile Nellrrl.ods). SV was calcul>led !ISing lhe Modolrtow 
rnelltOO ilia, inclu ...... aF ... x, ooglll , and ",cigbt in its a1gorilllm 
(lkalSOOpe '",,";00 1.1; RO'Jlf~' Medical SY."'III5) (S) and has Mil 
$lI()y,'n 10 :>e<:ur3,ely ,~~ CO ciuring a ''3Oe'y of up;'rin~nlal 
pr(l(OC<JI$ inclu<iing e .... rci$t (9 , 10. +I, 44a, 46). CO Wail llIen 
e>lcula<edu 1Ir ~CI ofUR and SV. V8$<ulor coodowl!lce .. "hiD 
e""h 10, ",as cakul.led as Jog blooo:l dow/MA P. 
~ (J('quilili~. Tk>;>ug/J()U' 1Ir eoti .. pr-QIOCQI, HR, SV, CO, 
MAP, E(;C;, ,"d ~Il<. join , .ngle signals ""Ik,won< .nalog"o)-djp,oI 
CQn",sio" 31Id w .... sj[llUllOll<o ... I)' acqlri,.d (200 Hl.\ using com· 
ll""cially .v:.jlablc .,., ... a.cqui$iricol lOfI ... -aro (Acq Koowltdge. Biopilo: 
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HJ6SS 
(10.000 Hz) u... audio .m<-ro&f3de and relroft3de sign31s from bolll 
Doppler uUT.I"",,1X! .)'."'ms lo ... rve as. qualiIJIi'" illdiClIOf af blood 
w locily challjles and '0.[0$"'" an occllf:Ite lemporal alig ...... '" of 
blood wloory measuremeots obtained rrom lhesc S)'SI<'OlS and the 
<>lb. .. sigmls coIkCk<! (i. •.• fillOllle l<r and gonioOl"l<1) (30~ 
SUlIiJl;caI Alla/),,,,,, 
SUtistiCl w.", perfO<IDed using ronmorcially .,";I>bk Ioflw"". 
(S PSS, v, \7.0, <'10"'&0. IL~ All ill¢pelJli<m "'''$1 (u < 0-05) was 
u$<d 'o~ FMI) ~I " RH io HT~ ",c;pi<1tI$ ""~OInrol$. A$ both 
0:011'31 ,"d peript",aI "'$~' "'«e ''''nS1rfll, only <b,1O from [II< 
fir51 40 $ of p3S$i "e '11O"~nl<m We ... ~, and bd~ . ,."')'';$ oIt 
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The (s ) 
MS. l. C<ott>! oaJ p<ri~he"" h,m»<lj">mic 
.... 1""'_ 10 _'" ... m .. ;. he", """, 
pI> .. (lIT» <'O<ipOt ....... " .. tII>lo. Vil_ ... 
...... :0 SJ; of pu":, .. los bJ<><>d ft_ (A). 
",1IUOI1os_ ftow (B~ ,anI;"; .. pot (CO. 
C). hc", I'OIe(IIR,D)._roI''''''(SV.I:). 
... ' .... " _nlll "... ... .., (MAl'. f') f..- II>< 
fu>I 40 • of Ihc <>«,,;11< Pf<'I<"oJ. bplil. 8< ..... 
..;.. Tho ....... ; .. ftom .... '" _\~n.'" 
0".,." " 0".,,,, ''''. N ........... fiS'''''''' 
_.IOd'.ill ....... lhcg< .. ntI' .. ,." . .... ,r.. 
.. Ill~ .... ~'< .. ptdO>moo.! • • d ... (",on i.,j;';d-
,m ~'ho eUlibiled valyil\! ... poaoe kioeti<" 
"" .... si.g ~D'''~ • ......, of ,1-00 ;'1_'00 i. 
lbo origioal iad"id .... I«OrulOgo. Thor<fot< . 
..... ""'''' , .... g< I."", '" l'< "oIc<o$rinlOlOd 







0.05) w .. u""d 10 COOIlX"e ,,-llotlrr ;n<Ii'i"":tl muimal rel.u"e 
ellan&,", ill CO. It R. SV. and blood now diff.red from baseline willill 
each VWPO .nd.n ;n<kpondeDlI.IeOi (e. < 0.05) ... os used lo;<lentify 
diff"",1K>!'S rei"''''''' lloolllly control, and HTlI recipients. A paired 
I·IOS! (e. < 0.05) wa, oIso used 10 COOIpa'" <.'OlIIfOl leg blood no'" 
re'pOI>!t. from ~>1 ~wly,no\"td leg \\';,hine:w:h group. All group 
d..., . .,.. .~~$$td it me.". "'- SE. 
Rt~"lJI.TS 
Peripheral Respo1!$t'S /0 PO$$;"e Exercise 
TIle peripheral blood flow re<ipom;es 10 p.ush·e movement 
on.- lime arc illustrnled in Fig. I. A :vld n, .00 aU mAXimum 
chan$,es from bllSeline arerepmenle.::1 in Fig. ~. Baseline blood 
flows ,,'cn:: not diffcrcnl bclwc.:n I-ITx rccipicnlS (218 :!: 29 
mtlmin; 237 :!: 6S ml/min) and cmlrols (259 :!: 41 mtlmin; 
154 :!: 29 ml/min) in Ihe psssive ""d ronlrolleg, re.;poclh'e1y. 
Following the onset of pas:>iv" movernenl. the rn3.1l;murn blood 
flow :w:hie\'ed in lhe paloSively moved leg. in<;reased signi6-
canlly sbew" baseline in boIh Hn. recipients (397 :!: S3 
mtlmin. J.SS%) a.nd e<>ntrols (623 :!: 78 mIImin. 11156%) 
altklugh al1t:nualed in the I-ITx recipients (Fig. 2). In Ihe I-ITx 
rtt ipients. Ihc percenl chansc from base~ne (Fig. 2) in the 
p.ossivcly m",~d leg "'$ nOl signific-'I1tly diffcrmt from the 
control kg. unli ke the ronlrol group where Ihero ,,'(1$ a signif-
ical1! difference betweenleg.~. nle lransient irn;reasein fem<xal 
blood now. as assessed by 1M AVe during the firsl 40 G of 
p.1$$ive limb movemenl. res\llted in a smaller blood Volume 
enlering the leg in Ihe I-ITx «:cipicnlS (24 :!: 8 ml) comp.,-oo 
WiU1 U,e ronlrO\s (93 :!: 25 mI). 
Cmllral Respollses 10 PGSsil'e Exerciu 
1hc central r<:sponscs 10 passive rno,'cmenl oVCf time arc 
illUSlraloo in Fig. I. C- F. R=linc v.lucs for eo ""d SV WCI"e 
not signi6can\11' differenl bct,,;een the liT): recipients and 
cOlllrols: however. !herc were baseline differences inllR (p -
OJ))I) and MAl> (p = 0.05). All maximum chang"" from 
baseline ar" represenled in Fig. 2. The IITx r~";pients dis_ 
played a significanl increase in eo (0.4 :!: 0,1 tlmin. J.S%) 
3ltmugh Ueally 3ltenualcd. compared willi Uwcontrols (1,0 :!: 
0.2 IImin . .118%). In the /-ITx recipients. there was:in abl;mc;.l 
of 3 significant increase in HR (0 :!: 0 bealS/min. .10%). 
Therefore, lheeo re:;prnse was solely dependent on increased 
SV (5 :!: I mt ~5%). These cenlrnl ro!SjXl~ in the I-ITx 
recipients were accompanied by a signific41,t decrease in MAP 
(- S :!: I mmHg. J. - S%). In COrttr3st. the COrtlrols who 
signific-'I1tly increased IIR (6 :! 2 bc.lISImin. ~ II%) as well3S 
SV (S :!: 2 rill. ~ 7%) exhibited "" increase in MAP (7 :!: I 
mmHg . .17%) (Fig. 2). 11"" m:uimal c/\3nges in l-'lL';<;\Ilar con-
duct.mce in the passive leg ... :ere greata in the COOlrois (3 :!: I 
ml·min-'·mmHg-', ~ 1S6%) compared "'ith llIe H1): recipients 
(2 :!: 0.3 mhnin- <'unuHg- '. ~87%). 
Vascular FW1C1i011; FMO and RH 
TIIere was no significant difference in periplleral ""-SCIllar 
function bel"·...,n the HTx r«ipk'nts :vld conlrols as assessed 
by FMD (Fig . 3). TI,is was the ease whether f').1D was 
cxpr(sscd in Iradilional lerms (%diameter change) (controls. 
6 :!: 1%; m:I HTx recipimts. S :!: 2%) a- na-otlI~2ed fOf ,;hcar 
rate (FMDlslle:rr rate) (conlfols. 0.1 :!: .02; and I-ITx r("ipicnts. 
0.2 :!: 0.06). Resling brachial ariel)' blood flows did not differ 
belween conil"ois and lUx rttipients (110 :!: 15 and 90 :! II 
mllmin, rcspectively) (Fig. 4). Simil1rly. RH. OOIh in terms of 
peak (conlrols, 805 :!: 64 mVmin; and IITx recipients. 680 :!: 
64 mllmin) and Ave (<<:nIroIs. 611 :!: ffl D~; 300 I-ITx ~
~ :!: 58 ml), ".~ net differdll betI>-. groups (Fig. 4). 
DISCUSSIOS 
In ibis study. we sought 10 dc:laminc Ow caw-al.m:l paiphc.-al 
rollributicns to 1IlO"emenl-induced hyperemia in response to 
p:>S'iiw 1IlO,'Cmcnr by comparing humlns will, a dcnCIVOIed heart 
orl'x) kl intact controls. With U,js approa:.:h. we ~-ed a 
fourfold n:<luctkn in die il"OI'"I'iil'lI increase in fCDlQ"al blood 
volume mlering Ule leg in response to passi"e limb trlO'emeni in 
\he llTx r«ipioots compared " 'iU1 COOIrOlol. This attenuated hy_ 
peremic resptn>C 10 [1lO\'cmml in Ihe I-ITx nxipimts " 'as not 
likely due 10 diminished perip" ..... 1 vaseul.,- function. (1$ me:lSUred 
by br:lchioJ artc-ory FMD and RH. implicaling a differing eerllroJ 
hemodynamic r;::spol~ as llIe source of d~ity in leg blood 
~ow. 111elSC findings higl~igl' die key role of ~'" retk.'< ~ 
in HR and Ute ~ialed rise in eo re>pcruc as an importanl 
mechanism IIIl11 C<XIlTI"bu\e$ 10 nto"emcnr-induce<l hyperemia in 
hum.ms. 
C ... ,/ral Qud P"ripheral Respo1!Ses la POSS;I'f! 
limb M(f>'"melll 
Almost insbnUnoously upoo tI,e initiation of leg movement 
in II", conlrol subjects. ~Ie<"e was a significanl increase in flR 
(Fig, I), which "'llS likely due 10 U1e slimul9lion of peripheral 
muscle 4l1d joint afferenl refte~cs ( 1. 2. 32) and subsequelll 
vagal inhibition (33). This HR increase COrtlribuled 10 the 
.- -~- - -~- --=~. 
Fi!. 2. ).to.; .... m ,<!.t,,,, d ... S"";. r-iv< 
"SblMd ft_.< ... n>llogbl""" A_,""""'" 
< .... ""' . .. ;e. CO. HR. S\'o • • d MAP " IfI)o 
,"""pie ...... ~. v., .. , ... mo •• , :!: 
SS, ·S~.;fiu.'11 ",",,,,,, [,,, .. <"..-01, Nooo, 
1',,-,u "".ale rot tho blood now .Jato io .titI"<J>:" 
(.0" ,. .... ""ole for ''''' <c ...... ""-;",,10. 
(d .. hoJ "",i<oI Iio< .. pat>!<, ''''' ""-;",,10. 
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Fig. 3. Brachial art~ry flow-m~diat~ dilation (FMU) following 5-l1lin cuff 
occl usion e;ttpressed as a ~rcent change from precllff baseline (A) and after 
nocmalizing FMD for sh~ar rille (8) in HTA n:cipients and controls. Vah,,:s ar~ 
means:': SE. There were no siguificanl differences. 
increase in CO (- 18%) in the cont rol subj ecis. '[11C liming and 
magnitude or both these responses was similar to recent results 
publi shed by our group (30), which suggesled that an HR-
driven increase in CO is a primary initi ator or movement-
induced hyperemia . Despite baseline values thai were not 
sialisl ically different, (here was no J-IR responsc 10 passive 
limb movement in (he IITx group, whi ch confimled tlle appro-
priateness of using HTx recipiems as a model devoid of a 
chronotropic response (Fig. I). Interestingly, HTx reci piems 
also exhibited a significalll increase in CO (- 5%) with passive 
limb movement. Whetl compared with that of the lIonnal 
controls, Ihis CO response was reduced in magnitude and the 
liming of the CO increase was delayed by II to 12 s. This 
delay related to the fact that the CO increase in HTx patients 
was solely dependent on an increase ill SV rather than HR. 
Previous studies have suggested that an increase in limb 
blood flow and the resultant rise in venous retum could be the 
predominant mechanism responsible for an increase in CO 
willI passive limb movelllent (14). [n the present study, there 
was no difference in the magnitude of SV increases between 
the controls and the HTx reCipients and. as already noted, the 
SV response was similarly delayed in both groups, perhaps 
indicativc of the transit time for Ule increased blood vo[wne to 
travel Ulrough the passively Illoved leg (3) and tben rctum back 
to the heart. AIUlOugh long-established hemodynamic princi-
pi es demand tilat an increase in venous retllm is required to 
sus tain an increase in CO, the temporal relationships between 
S V, HR, and CO documellled in this study suggest that in the 
first few seconds of Limb movement, there may be a mismatch 
between CO and venous retum , such that the initial increase in 
CO can be attributed to the almost instantaneous increase in 
HR. This observation is emphasized here by Ihe lack of an HR 
response and a subsequently delayed and attenuated CO in-
crease in the I-ITx recipients (Fig. I). 
Upon iniliation. passive leg movement consistcntly result s in 
an increase in femoral blood flow (1 4, 30. 5 1). As hypoUle-
sized, hyperemia in the passively moved leg was sigllificaml y 
atte nuated by approximately fourfold in the HTx recipients 
(Figs. I and 2). and much of Ule observed difference in 
maximulll blood flow betweellthe controls (- 156%) and Ule 
HTx recipients (- 85%) could be allributed 10 the lack of an 
HR increase and Ule concomitantl y diminished CO response. 
The differing hyperemic response between these groups furtll er 
supports the previous conclusions from our group (30) thai an 
HR-driven increase in CO is an essential component of the 
hyperemic response at the onset of leg movement and that limb 
vasod ilation and the subsequent venous retum are not solely 
responsible for the increased CO in the first few seconds 
following limb movement. 
MAP and Vascular Conduc{(lllce 
During passive leg movement. there was an increase in MAP 
(- 7 mmHg) in the control subjects, an expected effect of an 
increase in CO and the concomitant change in vascular con-
duc tance. However, this intuiti ve finding is in contrast with our 
previous study (30), which reported a small decrease in MAP 
(- - 3 mmH g) upon initimion of passive leg movement. '111is 
discrepancy may be a result of age-related differences in 
vascular functiOll and/or structure (6. 28, 31, 48) mId barore-
ceptor refl exes that previously minimized this potelllial for a 
ri se in blo<Xl pressure with an increase in CO as fhe present 
control group was older (- 58 yr) compared with the group in 
our previous study (- 33 yr). 'nlUS perhaps barorefl ex control 
of HR in response to limb movement plays a more important 
role in young rather than older subj ects. In contrast, MAP in 
the HTx recipient s exhibited a compamblc magnitude of 
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Fig. 4. Resting brachial anery blood flow and reactive hyperemia following 
cuff occlusiOIl in healthy controls and IITx recipients. 







chru1ge 10 Ole currctll age-!TI:IIChed controls bul in tI>e opposite 
direction ( ... - 5 mmHS). This was mosl likdy a oonseqUenc.! 
of a drop in peripheral ,"""i~tar-.:e by m~h"llically induced 
vessel dilation (8. ~) and FMD (25. 26. 34). allo"'ing blood 
flo,,· to ir\Cre.1SC to the passively ITIO\'ed limb but withall the 
same magnitude of CO increase documented in the controls to 
either raise or successfully m3intain MAP. [)e~pite the CQn-
lusting and signific:mt ch:mges in MAP. v3SCUI"l" conduet:mce 
was qualitati"ely very similar to blood flo,,' " 'ith the maximal 
change Ixing f"l" greater in Ule controls romp",ed with Ole In'l<; 
rttipients (FiS- 2). Thus the difference in hyperemia obsen'a1 
bet"'een Ole t,,·o groups could not Ix explained solely by 
eh:mSes in MAP. 
Peripheral V~$ClII~r Fmll;licn 
Diffcrellccs in the hyperemic response to leg movement 
bet"""'"'" the l-IT~ rttipients ond conll"ol$ could con~i,·.bly be 
attnbuted to differern:a; in peripheral \'3SCUI"l" function as a 
result of the prior disease swe. inckpendent of celltr:l.1 C"l"rua.:; 
differ<:nces. &-ripheral v9SCUlar dysfunction is kno"'n 10 OCCur 
in chronic heart failure (II. 12. 20. 21). Il""·,,,·ct". somewhat 
surprisingly. there is evidence that endolhdial function im_ 
proves widlin the first 12 mo following lI"anspl:mtation (27. 
39). III 'gr""",,,,,l " 'ith this concept the pe:ipheral v-'SCnlar 
funetioo of the clUTent In-x recipients. as asseo;.scd by braChial 
mery FMD and RII. was 1101 atlrouated (Fig ... 3 and 4). This 
further supports thaI U,e limited femoral blood flow kS~ in 
this group was a result of U,e lack of an HR reoip<m:>C and not 
periphcul v:lSCUlar dysfunction. AltllOUF,h FMD and RH are 
jusl t,,·o of Ute jXlSSib1e me3Surcs of vasculAr functia!. these 
observalions of v3SCUl", normalcy also support lh<: usc of the 
frTh palient m<XIcl to elucidate the importance of fiR and CO 
on movemrot_indu~ hyperemia. 
Clinic~1 PerspeClil'e 
Follo .... ing I n'<. recipirots ""hibil subiitantial exercise intol-
cn.nce (19. 35). particularly in the initial years following the: 
prooedure (17. 41 ). Many studies have demonstrated an asso-
cialion between e.~ercise inloler:ul~:md chronotropic incom-
pclroce (15.19.38.40). TIle l-ITx recipienls in O,is stndy also 
demonstrated a lack of an HR response aoo an attenuated 
hyperemia at the: initi3lion of passive limb movement. Al_ 
though still contro\'Crsial. there is accumulating cvidellce sug-
gesting!Wllle sympaOtetic reinnervation occurs in lIT. recipi_ 
ents based on a more rKirmal chronotropic "nTcire ~
(15.40). evidence of coronary norepinephrine spillover (43. 
47). and HR variabilil)' (23). The passive limb ![)()\'ement 
approach used in this study helps to illustrate d"'t other 
,nc<;h:misms besides HR (i.e .. SV) increase CO in this popu-
lation. Addit;on,l!ly_ such a paradigm may pro"ide cHnici:ms 
and lherapists willI :mother tool with which to eumine the 
impact and role of cardiac reimer-'alion withoul the addOO 
complc~ity of U,e c":mging metabolites asso<;iated WiU, e>lct"-
eise. 
Experimenlal Considerll1iollS 
Althougll many subject chamctcristics and vascular function 
of Ute !-IT. recipienls were not diffacnl from the controls. it 
muS! S!iI! be acknowledged that_ in ;><\ditlon to the main reason 
for studying this population (a lack of cardiac i~,,·ation). the 
lrTh recipients all previoosly had lteart failure. Thus the 
recognized s~eletal muscle dysfunction associaled "'i!h lhis 
pathology may have influeuced Ule r""ults of 1llis study: how-
c'·cr. this issuc was likely minimized by the. fael lhallhis study 
employed passive eJten::ise which does not require a significant 
skeletal muscle metabolic respms<:. An addiliorl3llimitation of 
this study is Ihe e:o:trnpolalioo of peripheral vascular function 
from tlte upper to the lower limbs. where the response 10 
passive movement was acrually assessed. 
SIU/millry 
\ViUI 0", use of the (\merv3.ted 1m p3tiertt model. these dau. 
pl"O"i<\e. ""idence t/u.t an ekWatiOll in IIR:md Ole $lIbrieqUenl CO 
ir>I:rea!le are an important rontributor to 11., hyperemic response 
follo"'ing U., onset of (>Wi,"e ~mb IIlC)\CUlCn!. "Ill<: attcnualal 
blood fIov,. ~ in the HTx recipients CII/lnot e:<'!ily be 
c~plained b)I diffCltl"lttS in peripheral vascular fWlCtion.:IS FMD 
and Rlf "-crenot allenuted in 1lle IITx redpi"'ts. TI-.:se fiOOinl'S 
higNighl dIe ~ey role of Ole retle~ in fiR oro Ole 
associated ri$e in CO re$pon$¢ :IS an JmporIMI mechanism for 
!IlO\'em"l1-induc<rl h)-p<:fem;a in hum~ 
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EVIDENCE OF ALTERED VASCULAR FUNCTION AND THE ROLE OF 




Using flow-mediated vasodilation (FMD), reactive hyperemia (RH), and an acute 
oral antioxidant cocktail (AOC (Vitamin     	
	 	, this study aimed to 
provide greater insight into altered vascular function and the role of oxidative stress with 
the development of chronic heart failure (CHF) and over time following heart transplant 
(HTx) surgery. Twelve healthy controls (58 ± 4 yrs), 14 CHF patients (62 ± 2 yrs), 12 
recent (< 3 yrs post) HTx recipients (58 ± 3 yrs), 12 (5-10 yrs post) HTx recipients (59 ±
4 yrs), and 11 (> 14 yrs post) HTx recipients (67 ± 2 yrs), ingested either placebo (PL) or 
AOC prior to FMD and RH testing. Vascular function, as measured by FMD, was not 
different between the controls (6.8 ± 1.9 %), recent < 3 yrs post-HTx group (8.1 ± 1.2%), 
and the 5-10 yrs post-HTx group (5.5 ± 1.0%).  However, PL FMD was lower in the CHF 
patients (4.5 ± 0.7%) and in the > 14 yrs post-HTx group (2.9 ± 0.8%).  The AOC
increased plasma ascorbate levels in all groups, but only increased FMD in the controls 
(PL 6.8 ± 1.9%; AOC 9.2 ± 1.0%) and  > 14 yrs post-HTx recipients (PL 2.9 ± 0.8%; 
AOC 4.5 ± 1.3%), and RH had no effect in all groups. Thus, vascular function is blunted 
in CHF patients, normalizes soon after HTx surgery, but progressively declines to a level 
similar to CHF patients with free radicals implicated in this progression.
Introduction
Vascular endothelial dysfunction is a systemic pathology that impairs the health 
and vasomotor control of both conduit and resistance vessels.  Impaired endothelium-
dependent vasodilation has been associated with various cardiovascular diseases 
including hypertension (36), coronary artery disease (33), and CHF (10, 23), but more 
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importantly may also precede the development of these conditions (5, 6). Therefore, in
these patient populations, as well as healthy individuals, endothelial dysfunction may be 
of prognostic value and consequently noninvasive tests such as flow-mediated dilation 
(FMD) (5, 6) and the measurement of reactive hyperemia (RH) (20, 32) have become
common research tools for the assessment of vascular function. However, the real impact 
of disease progression and surgical intervention across the continuum from health, CHF, 
HTx, and beyond has not been well characterized.
CHF patients have chronically elevated peripheral vasoconstriction, the result of 
elevated sympathetic nervous system activity (17), the renin-angiotensin system (13),
and a concomitant dysfunction of the peripheral vasculature (23). The latter appears to 
be the consequence of an attenuated L-arginine-nitric oxide pathway (24) and has been, at 
least partially, attributed to the increased destruction of nitric oxide (NO) by free radicals
(1). Elevated levels of free radicals, particularly superoxide (O2-), contribute to decreased 
NO bioavailability (49) and the corresponding attenuation in endothelial function (8).
Antioxidant supplementation, presumably by improving NO bioavailability, has 
previously restored endothelial function in healthy aged individuals (8, 12) as well as 
CHF patients (18). Interestingly, in CHF patients that have undergone a HTx, there is 
some evidence that endothelial function normalizes relatively soon following 
transplantation (26, 41), although this is still somewhat controversial (37, 43) and the role 
of free radicals in this apparent restoration of function soon after HTx and then beyond is
unclear.
Accordingly, using FMD and RH to assess vascular function and an acute oral 
AOC to examine the role of free radicals, this study sought to provide greater insight into 
17
changes in vascular function with the development of CHF, HTx, and beyond.  We
hypothesized that 1) when compared to controls, vascular function as assessed by FMD 
and RH, will be reduced in CHF patients, improved immediately following HTx, and 
progressively decline thereafter and 2) by attenuating the levels of free radicals, the 
ingestion of the AOC will improve vascular function in all groups with more pronounced 
effects in the CHF patients and the HTx recipients with a longer time post-surgery.
Methods
Subjects 
A total of 61 subjects (12 healthy controls, 14 NYHA Class II and III CHF 
patients, and 35 HTx recipients (< 3 yrs post-HTx, 5-10 yrs post-HTx, and > 14 yrs post-
HTx)) were recruited in the CHF and HTx clinics at the University of Utah and the Salt 
Lake City VA Medical Center. The protocol was approved by these institutions and 
written informed consent was obtained. Characteristics and the pharmacological therapy 
of the CHF and HTx recipients at the time of the study are reported in Tables 3 and 4.
All studies were performed in a thermoneutral environment at least 3 days apart to allow 
for washout of the oral antioxidants. Subjects reported to the laboratory in the fasted 
state, and without caffeine or alcohol use for 12 and 24 hrs, respectively.  They had not 
performed any exercise within the past 24 hrs and if antioxidants and/or a multivitamin 
were part of a subject’s daily routine they were asked to refrain from such use for at least 
three days prior to testing days.
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Brachial Artery Flow-mediated Dilation (FMD) and
Reactive Hyperemia (RH) 
Subjects rested supine for approximately 20 min, and a blood pressure cuff was 
placed on the upper right arm proximal to the elbow, but distal to the placement of the 
ultrasound Doppler probe on the brachial artery.  Baseline measurements of brachial 
artery diameter and blood velocity were performed, and the arm cuff was inflated to a 
suprasystolic pressure (>250 mmHg) for 5 min.  Brachial artery diameter and blood 
velocity were then assessed continuously for 2 min following cuff deflation.
Antioxidant Supplementation
Subjects received either the AOC or placebo in a balanced, single blind design for 
the subject’s two visits.  The supplements were administered 90 and 60 min prior to the 
FMD protocol. A split dosing was used to improve absorbance and distribution of the 
antioxidants.  The first antioxidant dose included Vitamin E (200 IU), Vitamin C (500 
mg), Alpha-lipoic Acid (300 mg), and the subsequent dose included Vitamin E (400 IU),
Vitamin C (500 mg), and Alpha-lipoic Acid (300 mg). The placebo microcrystalline 
cellulose capsules, that were of similar taste, color and appearance, were also consumed 
in two equivalently timed doses.  The efficacy of this AOC to reduce plasma free radical 
concentration has previously been established using ex-vivo spin trapping and electron 




Brachial artery diameter and blood velocities were measured with Ultrasound 
Doppler using a General Electric (GE) Logiq 7 ultrasound system (GE Medical Systems, 
Milwaukee, WI, USA).  This system was equipped with a linear array transducer 
operating at an imaging frequency of 12-14 MHz, with frequency selected to optimize 
image quality according to vessel depth (16). Blood velocity was obtained with the same 
transducer with a Doppler frequency of 5 MHz. An insonation angle of 60º or less was 
utilized and the sample volume was centered within the vessel and maximized according 
to vessel size. The same experienced sonographer performed all measurements.
Brachial artery diameter, blood velocity, and blood flow analyses
Analysis of arterial diameters were performed off-line using the automatic edge-
detection Brachial Analyzer software (Medical Imaging Applications, LLC, Coralville, 
IA).  Angle-corrected and intensity-weighted mean velocities (Vmean) were determined 
using commercially available software (Logic 7).  Using Vmean and arterial diameter, 
brachial artery blood flow was calculated as:  Blood flow = Vmean	 diameter/2)2 x
60, where blood flow is measured in milliliters per min.
Shear rate and reactive hyperemia calculation
During an FMD test, laminar shear stress is believed to be the mechanism that 
stimulates the vascular endothelium and results in subsequent vasodilation of the brachial 
artery (53). However, as blood viscosity was not measured, shear rate, which can be an 
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adequate surrogate measure (39), was calculated using the following equation:  Shear rate 
1) = 8Vmean /arterial diameter. Cumulative shear rate (s-1½s) (area under the curve, 
AUC) and the reactive hyperemia post cuff release (total blood flow over 2 min) were
	 	  
	     i(x(i+1) - xi) + (1/2)(y(i+1) -
yi)(x(i+1) - xi)). 
Oxidative stress, and antioxidant assays
In both the placebo and antioxidant trials blood samples were obtained from the 
antecubital vein prior to FMD testing (1 hr following ingestion of the second dose of 
either AOC or placebo). Serum and plasma samples were stored at -80°C until analysis. 
Quantitative determination of thiobarbituric acid reactive substances (TBARS) was 
performed to assess lipid peroxidation (54) (Bioassays Systems, Hayward, CA). 
Endogenous antioxidant activity, assessed by superoxide dismutase (SOD) and catalase 
(CAT) activity, were assayed in the plasma (51) (Cayman Chemical Company, Ann 
Arbor, MI) as well as ascorbic acid levels (3) (CosmoBio, Carlsbad, CA). A lipid panel 
and complete blood count were assessed by standard clinical techniques.
Statistical Analyses
Statistical analyses were performed using commercially available software (SPSS 
17.0, Chicago, IL). A repeated measures analysis of variance 2x5 (ANOVA) "#"$
was used to determine if the oxidative stress/antioxidant assays and vascular responses to 
placebo and antioxidant supplementation for FMD and RH differed between healthy 
controls, CHF patients, and the HTx groups. Tukey’s Honestly Significant Difference test 
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was conducted to evaluate pairwise differences among the means. A one-way ANOVA 
was used to determine differences in subject characteristics. All data are expressed as 
means ± standard error (SE).
Results
Subject Characteristics
The healthy controls, CHF patients, and HTx recipients were well matched for 
age and most other physical characteristics (Table 3).  Other than disease state and
subsequent medications (Table 4) there were only significant differences between groups 
in terms of blood glucose, low-density lipoprotein (LDL), hemoglobin, hematocrit, and 
red blood cells, however, most values fell within the normal range (Table 3).
Flow-mediated Dilation (FMD)
Baseline vascular function, as measured by PL FMD, was not different between 
the healthy age-matched controls (6.8 ± 1.9 %), recent, < 3 yrs post-HTx group (8.1 ± 1.2 
%), and the 5-10 yrs post-HTx group (5.5 ± 1.0%) (Figure 5).  In contrast, PL FMD was 
lower in the CHF patients (4.5 ± 0.7%) and in the > 14 yrs post-HTx recipients (2.9 ±
0.8%) compared to the controls. There was a significant negative correlation between 
time post-HTx and PL FMD (r = -0.52) (Figure 6).  The antioxidant intervention 
increased FMD by 35% in the controls (PL 6.8 ± 1.9%; AOC 9.2 ± 1.0%) and by 55% in 
the > 14 yrs post-HTx recipients (PL 2.9 ± 0.8%; AOC 4.5 ± 1.3%).  The AOC had no 
measurable vascular effect in any of the other patient groups. Shear rate was not different 
between groups and therefore was not utilized to normalize FMD was not normalized for 
shear rate.
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Resting Blood Flow and Reactive Hyperemia (RH)
Resting blood flow did not differ between healthy controls, CHF, and HTx 
recipients (Figure 7A).  Similarly, RH, both in terms of peak (Control 742 ± 77 ml/min,
CHF 707 ±  104 ml/min, < 3 yrs post-HTx 845 ± 97 ml/min, 5-10 yrs-post HTx 858 ± 93 
ml/min, and > 14 yrs post-HTx 936 ± 170 ml/min) and AUC (Control 561 ± 65 ml, CHF 
625 ± 87 ml, < 3 yrs post-HTx 673 ± 82 ml, 5-10 yrs post-HTx 728 ± 82 ml, and > 14
yrs post-HTx 589 ± 71 ml) , was not different between groups.  There was no effect of 
the AOC on peak RH (Control 724 ± 89 ml/min, CHF 705 ±  98 ml/min, < 3 yrs post-
HTx 781 ± 88 ml/min, 5-10 yrs post-HTx 796 ± 92 ml/min, and > 14 yrs post-HTx 760 ± 
72 ml/min) or AUC (Control 549 ± 85 ml, CHF 578 ±  83 ml/min, < 3yrs post-HTx 651 ±
75 ml, 5-10 yrs-post HTx 696 ± 115 ml, and > 14 yrs post-HTx 548 ± 62 ml) (Figure 7B).
Oxidative Stress and Antioxidant Capacity
Baseline (PL) plasma ascorbate levels were significantly higher in the controls 
compared to all of the patient groups (Figure 8A).  The AOC significantly elevated 
plasma ascorbate concentrations in all groups 2 hrs after the ingestion of the first dose 
(Control 16.3 ± 2.1 to 26.9 ± 1.8 ug/ml; CHF 13.7 ± 0.7 to 20.7 ±  1.2 ug/ml; < 3 yrs 
post-HTx 12.9 ±  1.0 to 19.4 ±  4.7 ug/ml; 5-10 yrs post-HTx 11.7 ±  1.2 to 15.6 ± 1.7 
ug/ml; > 14 yrs post-HTx 12.5 ± 0.6 to 16.3 ±  1.2 ug/ml), although all the patient groups
still exhibited significantly lower levels than the controls (Figure 8A). TBARS did not
significantly differ between groups (Figure 8B).  However, with the exception of the 
patients with CHF all groups exhibited a tendency for a reduction in TBARS following 
AOC ingestion with the < 3 yrs post-HTx and > 14 yrs post-HTx groups nearing 
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significance (p = 0.07 and p = 0.06, respectively). Measures of SOD and CAT were not 




This study sought to determine the changes in vascular function and the role of 
oxidative stress from health to the development of CHF, HTx, and beyond. Utilizing 
FMD to assess endothelium-dependent vascular function across the continuum, we 
documented reduced vasodilatory capacity in CHF patients, which was improved or 
normalized in early HTx recipients, and then an eventual decline in vascular function in 
the HTx recipients that were the furthest time from transplantation (> 14 yrs post-HTx) to 
a level that was comparable to, if not worse than, pretransplantation (CHF).
Interestingly, unlike the other patient groups, the acute ingestion of the AOC was able to 
significantly increase FMD by 55% in these > 14 yrs post-HTx recipients suggesting that 
free radicals, and the associated decrease in NO bioavailability, are largely responsible 
for their endothelial dysfunction. Somewhat surprisingly, RH, an index of microvascular 
function, was not different across the groups and there was no effect of the AOC,
highlighting the differing physiology/pathophysiology assessed by FMD and RH. Also 
of significant importance to the interpretation of these data is the fact that these 
observations across time (e.g., time post-HTx) were not confounded by aging as the 
controls and all patient groups were of similar age.  These findings not only highlight the 
transient nature of vascular function over the course of CHF development and following 
HTx but also reveal the significant deterioration in endothelium-dependent vasodilation 
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in HTx recipients who are one to two decades beyond surgery.  This ultimate decline, as 
with the controls, appears to be a consequence of a free radically-mediated reduction in 
NO bioavailability. 
Endothelial Function in CHF and HTx Recipients
It is well accepted that peripheral endothelial function is impaired in patients with 
CHF (10, 23), largely due to the reduction in shear stress as a consequence of an 
attenuated cardiac output, reduced levels of physical activity, elevated peripheral 
vasoconstriction, and neurohormonal activation. Data from the current study are in 
agreement with this dogma as FMD, a reliable noninvasive measurement of endothelial 
function, was significantly blunted in CHF patients compared to the healthy, age-matched 
controls (Figure 5).  Interestingly, vascular function appears to normalize rapidly 
following HTx and remain at this level for an extended period of time, as both the early
(< 3 yrs post-HTx) and middle transplant (5-10 yrs post-HTx) recipients, exhibited a
similar vasodilatory capacity to that of the controls.  Both Kubo et al. (26) and Roig et al. 
(41) documented a normalization of endothelial function within the first year following 
HTx, which is most likely a result of an improved cardiac output with the donor heart in 
place and a reduction in the elevated sympathetic stimulation common in CHF (28).
However, the endothelial function in HTx recipients as a whole is still somewhat 
controversial (37, 43).
To our knowledge, this was the first study to include healthy age-matched 
controls, CHF patients, and a comprehensive cross-sectional group of HTx recipients at 
three distinct time points following transplantation, particularly a group that was > 14 yrs
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post-HTx and actually averaging 19 yrs after surgery. With this approach, we were able 
to determine that although endothelial-dependent vasodilation, as measured by FMD, 
improves soon after HTx, vascular function eventually declines to a level similar to that 
of CHF patients.  Thus, despite having normalized central hemodynamics as a 
consequence of the donor heart, vascular function progressively declines as time passes 
following HTx (Figure 6) to a level comparable to pre-HTx (e.g., CHF) and is likely not a 
function of age-related changes, as age was very similar across all groups. Heart 
transplantation is a multifaceted intervention that not only normalizes central 
hemodynamics, but also requires a very invasive surgical procedure and the use of a 
foreign organ that comes with its own complications. Therefore, there are a multitude of
factors that may contribute to endothelial dysfunction after HTx, including
cytomegalovirus infection (38), exposure to cold ischemia (14), preservation solutions 
(40), reperfusion at the time of implantation (35), and, perhaps most significant and 
germane to those living for more than one to two decades post HTx, are chronic 
immunosuppression and complex long-term pharmacological therapy (22).
Cyclosporine is one of the original, most commonly used, immunosuppressant
for heart transplant recipients. Prior research has revealed that cyclosporine may result in
endothelial dysfunction (22), as it has direct cytotoxic effects on the endothelium (55),
impairs endothelium-derived relaxing factor release (48), and increases endothelin
production (4). Cyclosporine has also been linked to increased sympathetic tone, new-
onset hypertension, and impaired peripheral blood flow in HTx recipients (44) and this 
may, at least in part, be mediated by free radicals (7). Our data provide further support 
for the idea that long-term cyclosporine exposure contributes to endothelial dysfunction 
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as 75% of the > 14 yrs post-HTx recipients were currently on cyclosporine (Table 4).  
Although there is not as much evidence as there is for cyclosporine, some of the newer 
immunosuppressants, such as tacrolimus, rapamycin, and mycophenolate mofetil, also 
appear to induce dysfunction of the vasculature (22, 50). Future research is needed to 
determine the long-term vascular effects of patients who have predominantly received 
these later generation immunosuppression therapies compared to the patients using 
cyclosporine. In addition to immunosuppressants, corticosteroids, another crucial part of 
the pharmacological regimen of HTx recipients, have been associated with dyslipidemia 
and glucose intolerance in the transplant patients (29, 47), potentially also contributing to 
the apparent deterioration in vascular function following transplantation.
Reactive Hyperemia in CHF and HTx Recipients
In contrast to FMD, the RH response represents both endothelium-dependent and 
independent vasodilation of the microvasculature (30, 31), but is also inversely related to 
cardiovascular disease risk factors (32). We hypothesized that RH would follow a similar 
pattern to the FMD measurements, such that when compared to controls, RH would be 
reduced in CHF patients, improve immediately following HTx, and progressively decline 
thereafter.  In fact, resting limb blood flow and reactive hyperemia, both in terms of peak, 
and AUC were not different between groups (Figure 7).   Thus, there was no evidence of 
microvascular dysfunction in the controls, CHF patients, or HTx recipients, which is at 
odds with recently published data. Indeed, Mitchell et al. (32) with data from the 
Framingham Heart Study, revealed that RH was more tightly correlated to cardiovascular 
risk factors than FMD so it seems that this would be reflected in the RH response in the 
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present study. However, the body of literature related to endothelial-independent 
vascular function in CHF patients is quite equivocal (15, 25, 34) and there is convincing 
evidence that endothelial-independent vascular function is not attenuated in HTx 
recipients (26, 41). Therefore, we speculate that our normal RH response was largely 
influenced by endothelium-independent vasodilation which resulted in a less sensitive 
measurement, as compared to FMD, which would explain our lack of differences in any 
of the groups in either PL or AOC conditions. In support of this apparent dichotomy, in
peripheral artery disease patients, Huang et al. (21) found both FMD and RH to be 
significant predictors of cardiovascular events, but, of the two methods, FMD proved to 
be the stronger predictor of cardiovascular risk which could also potentially be attributed 
to the recent improvement and standardization in the FMD technique (16). It should also 
be noted that microvascular function does not necessarily equate to conduit vessel 
endothelial function which would also explain our divergent results with the FMD and 
RH tests.
Free Radicals and Vascular Function in CHF and HTx Recipients
It has been suggested that free radicals reduce vasodilation and limb blood flow 
by limiting NO bioavailability in the healthy older population (8), in CHF patients (1,
19), and  HTx recipients, especially those receiving cyclosporine therapy (7). Prior 
studies suggest that antioxidant supplementation can restore endothelial function in 
healthy older individuals (8, 32), and this is supported by the current study which 
revealed a significant 34% increase in FMD in the healthy controls following ingestion of 
the AOC. It is well accepted that heart failure is characterized by low NO bioavailability 
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stemming from a combination of an attenuated L-arginine-nitric oxide pathway (24),
reduced NO-synthase gene expression (46), a reduction of mechanical shear induced 
stimuli, and increased free radical formation as evidenced by increased plasma lipid 
peroxides (2). Previous research by Hornig et al. (18) suggests that endothelial function 
was improved in CHF patients following Vitamin C administered intra-arterially and 
following 4 weeks of oral therapy.  These researchers were also able to attribute the 
beneficial effect of the Vitamin C to be NO mediated by the use of NO antagonist NG-
monomethyl-L-arginine which attenuated the effect of the Vitamin C supplementation.
Therefore, we hypothesized that the ingestion of an acute AOC would attenuate the 
circulating levels of free radicals and improve vascular function with more pronounced 
effects in the CHF patients and the HTx recipients with a longer time post-surgery. As
illustrated in Figures 5 and 7, there was no difference in vascular function, as assessed by 
FMD and RH, following the acute ingestion of AOC in the CHF patients, the early (<3 
yrs post), or middle (5-10 yrs post) HTx recipients, which is not all that surprising 
considering the highly complex and varied pharmacological therapies of these patients, 
the low acute dosage of antioxidants given, and the relatively normal FMD responses 
seen in these two groups of HTx recipients. However, in the HTx recipients furthest time 
after surgery (> 14 yrs post), who had a significantly lower FMD and the longest 
immunosuppressant use, the AOC resulted in a significant 55% increase in FMD (Figure 
5), implying that this attenuation in vascular function can largely be corrected by 
decreasing free radical concentration and thereby increasing NO bioavailability.
Ingestion of the AOC resulted in a significant increase in plasma vitamin C levels 
(Figure 8A) in the healthy controls, CHF patients, and all the HTx recipient groups.  
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Thus, the AOC was able to increase circulating antioxidant capacity in all of these 
individuals. There was no significant change in TBARS that serves as a “footprint” of 
total oxidative stress, following ingestion of the AOC (Figure 8C). However, there was 
an overall trend for TBARS to decrease in the controls and all the HTx recipients but it is 
likely that the sensitivity of this assay was not adequate to detect acute changes, if any, in 
oxidative stress. Such TBAR results are supported by Silvestro et al. (45) who reported 
that in patients with intermittent claudication, there was no relationship between TBARS 
and FMD following vitamin C infusion and suggested that TBARS is unable to reflect 
acute changes occurring within the vasculature.
Our group has previously demonstrated that in healthy older individuals, the AOC
used here can effectively increase NO bioavailability to a level that can acutely improve 
endothelium-dependent vasodilation (8). This is supported in our control group by the 
elevated plasma ascorbate levels (Figure 8A) and the resultant significant increase in 
FMD, which is generally thought of as a bioassay of NO bioavailability (9). However, 
the pro- and antioxidant balance in the CHF patients and HTx recipients is likely much 
more complicated.  Ellis et al. (11) reported oxidative stress, as measured by TBARS, to 
be higher in CHF patients compared to controls, but within the CHF patients this 
response was more exaggerated in those patients with an ischemic versus non-ischemic 
etiology. The current study had an approximately equal distribution of ischemic and non-
ischemic CHF patients (Table 4) which may also contribute to the lack of effect our AOC 
had on the TBARS analyses.  Additionally, the study by Ellis et al. (11) reported that 
only long-term (1 month) Vitamin C supplementation had a significant effect on TBARS, 
whereas a short-term arterial infusion of Vitamin C at a much greater concentration had 
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no effect, again suggesting that this assay may not be appropriate for measuring acute 
changes.
Clinical Perspective
CHF is a major cause of morbidity and mortality in the United States and 
according to the American Heart Association is the leading cause of hospitalization 
among those individuals on Medicare (42).  In recent decades heart transplantation has 
advanced from an experimental procedure to an accepted life-extending therapy for 
patients with the most advanced stages of heart failure.  Therefore, as quality of life and 
survival rates continue to climb for HTx patients, there is greater interest in 
understanding the long term effects of HTx, particularly in terms of vascular function as 
this appears to be a good predictor of future cardiovascular disease (27). The present 
study suggests that although vascular function is initially normalized following HTx,
long-term immunosuppressant therapy may have extremely deleterious free-radically-
mediated effects on endothelial-dependent vasodilation. The documentation of declining 
vascular function as time progresses in the present study has potentially great clinical 
importance in the realm of cardiovascular risk and increasing quality of life in long term
HTx recipients.   
Conclusion
In conclusion, this study has documented that endothelial-dependent vasodilation,
determined by FMD, is reduced in CHF patients, and with a comprehensive, cross-
sectional approach has revealed a normalization of vascular function following HTx
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which gradually declines to a level similar to CHF patients in the years following 
surgery.  Interestingly, the attenuated vascular function in HTx recipients one to two 
decades following surgery is most likely related to decreased NO bioavailability, as an 
acute dosage of oral antioxidants and a likely decrease in free radicals significantly 
improves their FMD.
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Male/Female 10/2 13/1 11/1 10/2 9/2
Age (yrs) 58 ± 4 62 ± 2 58 ± 3 58 ± 4 67 ± 2
Weight (kg) 94 ± 4 97 ± 5 94 ± 9 93 ± 5 78 ± 5
Height (cm) 176 ± 3 177 ± 2 174 ± 4 180 ± 2 172 ± 2
Body mass index (kg/m2) 26 ± 1 31 ± 1 34 ± 7 29 ± 1 26 ± 1
Systolic blood pressure (mmHg) 127 ± 4 114 ± 2 124 ± 5 125 ± 3 120 ± 6
Diastolic blood pressure (mmHg) 79 ± 2 72 ± 2 77 ± 4 83 ± 3 73 ± 5
Glucose (mg/dL) 94 ± 4 137 ± 20 * 120 ± 15 93 ± 5 † 113 ± 14
Cholesterol (mg/dL) 175 ± 14 149 ± 12 146 ± 12 138 ±11 143 ± 6
HDL (mg/dL) 50 ± 4 39 ± 2 40 ± 2 42 ± 3 46 ± 5
LDL (mg/dL) 113 ± 13 91 ± 9 91 ± 10 75 ± 9 * 76 ± 5 *
Triglycerides (mg/dL) 101 ± 19 134 ± 18 116 ± 13 129 ± 21 154 ± 20
Hemoglobin (g/dL) 15 ± 0.6 15 ± 0.5 13 ± 0.4 *†‡ 15 ± 0.4 13 ± 0.3 *‡
Hematocrit (%) 45 ± 1.6 44 ± 1.6 39 ± 1.6 *‡ 45 ± 1.2 40 ± 0.8   ‡
RBC (M/ uL) 5.1 ± 0.2 4.8 ± 0.2 4.3 ± 0.2 *‡ 5.1 ± 0.2 4.3 ± 0.1 *‡
WBC (K/uL) 5.3 ± 0.4 7.5 ± 0.6 6.1 ± 0.7 6.5 ± 0.6 5.5 ± 0.5
Mean ± standard error; HDL, high density lipoprotein; LDL, low density lipoprotein; RBC, red blood cells; WBC, 
white blood cells. 
(*) Significantly different from control; (†) Significantly different from HF; (‡) Significantly different from HTx (5-
10 yrs).
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8/14 7/12 6/12 6/11
Diagnosis 
(non-ischemic cardiomyopathy)
6/14 5/12 6/12 5/11






History of Rejection (# of all cases) NA 1/12 1/12 2/12
Left Ventricular Ejection fraction (%) 29 ± 4 66 ± 2* 61 ± 2* 61 ± 2*
Diabetic (# of all cases) 6/14 7/12 3/12 6/11
Medications:
Cyclosporine (# of all cases) 0/14 2/12 4/12 8/11
Tacrolimus (# of all cases) 0/14 10/12 7/12 2/11
Azathioprine (# of all cases) 0/14 2/12 2/12 0/11
Mycophenolic acid (# of all cases) 0/14 9/12 7/12 5/11
Sirolimus (# of all cases) 0/14 0/12 4/12 2/11
Prednisone (# of all cases) 0/14 6/12 2/12 4/11
Beta-blocker (# of all cases) 14/14 1/12 4/12 6/11
ACE-Inhibitor (# of all cases) 10/14 6/12 5/12 2/11
Angiotensin Receptor Blocker 
(# of all cases)
3/14 2/12 4/12 2/11
Statin (# of all cases) 11/14 10/12 9/12 5/11
Diuretic (# of all cases) 9/14 3/12 5/12 3/11
Calcium channel-blocker
(# of all cases)
1/14 5/12 3/12 4/11
Mean ± SE; (*) Significantly different from HF
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Figure 5. FMD measurements in healthy controls, CHF patients, and three groups of 
HTx recipients.  (A) Brachial artery FMD following 5 min cuff occlusion expressed as a 
percent change from pre-cuff baseline in healthy controls, CHF patients, and three groups 
of HTx recipients.  (*) Significantly different from Placebo; (†) Significantly different 
from Controls; (‡) Significantly different from HTx (< 3 yrs). (B) Brachial artery FMD 
expressed as absolute change in diameter from pre-cuff baseline in healthy controls, CHF 
patients, and 3 groups of HTx recipients.  (*) Significantly different from Placebo; (†)
Significantly different from Controls; (‡) Significantly different from HTx (< 3 yrs). 
Values are means ± SE.
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Months post-HTx



















< 3 yrs post-HTx
5-10 yrs post-HTx
> 14 yrs post-HTx
y = 7.95 - 0.023x
r = -0.52 *
Figure 6. Time post-HTx and its influence on FMD (% diameter change).
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Figure 7. Resting brachial artery blood flow and RH following cuff occlusion in healthy 
controls, CHF patients, and three groups of HTx recipients.  There were no significant 
















Control - 561 ± 65 ml 
CHF - 625 ±87 ml 
< 3 HTx - 673 ±82 ml 
5-10 HTx - 728 ± 82 ml 
> 14 HTx - 589 ± 71 ml 
Controls 
4 HTx 
Control - 549 ± 85 ml 
CHF - 578 ± 83 ml 
< 3 HTx - 651 ± 75 ml 
5-10 HTx - 696 ± 115 ml 
> 14+HTx - 548 ± 62 ml 
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Figure 8. Quantitative assessment of antioxidant efficacy in healthy controls, CHF 
patients, and three groups of HTx recipients. (A) plasma ascorbate; (B) Thiobartituric 
Acid Reactive Substances (TBARS). Values are means ± SE. (*) Significantly different 
from Controls; (†) Significantly different from Placebo. 
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CHAPTER 4
EVIDENCE OF FREE RADICAL-MEDIATED SYSTEMIC VASCULAR 
RESISTANCE IN PATIENTS WITH CHRONIC HEART FAILURE
45
Abstract
To better elucidate the link between free radicals and hemodynamic control in 
patients with chronic heart failure (CHF), we studied 10 patients and 10 age matched 
healthy controls at rest and during handgrip exercise with either an acute oral antioxidant 
[	\]^	_		
		
`{|#To assess central and 
peripheral hemodynamics, mean arterial pressure (MAP), cardiac output (CO), systemic 
vascular resistance, brachial artery blood flow, and peripheral (arm) vascular resistance 
were determined. Compared to controls, patients with CHF exhibited greater oxidative 
stress, measured by thiobarbituric acid reactive substances (TBARS) (~40%), and 
evidence of endogenous antioxidant compensation, measured by superoxide dismutase 
(SOD) activity (~45%). The AOC increased plasma ascorbate by ~32% in both the CHF 
patients and controls. The ingestion of the AOC had significant systemic hemodynamic 
effects which were only evident in the patients with CHF, both at rest and throughout 
exercise. Specifically, the AOC further reduced the patients already lower MAP (~5%), 
increased CO (~10%), and caused a fall in systemic vascular resistance (~12%). In 
contrast, peripherally, brachial artery blood flow tended to be reduced, and peripheral 
(arm) vascular resistance was unchanged. Based upon the recognized link between free 
radicals and sympathetic nerve activity in patients with CHF, these data imply that 
systemic vascular resistance appears, at least in part, to be free radically-mediated;




In patients with chronic heart failure (CHF) exercise capacity and activities of 
daily living are often limited, resulting in decreased physical capacity and greater 
morbidity and mortality.  In these patients it is often assumed that exercise capacity 
depends on the severity of cardiac function (43, 50), but  ejection fraction  and measures 
of left ventricular performance do not always reflect exercise tolerance (16, 17). These 
observations have promoted the concept that the limited exercise capacity in CHF 
patients may also result from a complicated pathophysiology in the periphery that 
includes alterations in skeletal muscle (12), endothelial function (11, 19), and augmented 
sympathoexcitation (7).  Previous research has established that in CHF animal models 
(41) as well as CHF patients (30, 39), sympathetic nerve activity is not only higher at rest 
but even more exaggerated during exercise. This peripheral neural reflex, known as the 
exercise-pressor reflex, contributes to an increase in blood pressure, heart rate (HR), and 
peripheral vasoconstriction during exercise (40) and is thought to play an integral role in 
the regulation of blood flow to metabolically active and inactive vascular beds. While the 
increased sympathetic nerve activity in CHF is compensatory in nature it is most likely 
detrimental to exercise capacity (29), with the central and peripheral hemodynamic 
impact remaining unclear (15, 25, 55).
In vivo, oxidative stress represents an imbalance between free radical production 
and endogenous antioxidant defenses and is often associated with the onset and 
development of CHF (3, 20, 27).  Elevated free radicals, particularly superoxide, have 
been linked to peripheral hypoperfusion, peripheral endothelial dysfunction, and 
exaggerated sympathetic nerve activity in the CHF patient population (22, 44, 46), which 
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are all likely contributors to exercise intolerance.  Prior research, in an animal model of 
CHF, has revealed that decreasing free radicals by an arterial antioxidant infusion 
attenuated sympathetic nerve activity and MAP (22). Interestingly, in contrast to the 
decrement in central parameters, indices of oxidative stress have been closely correlated 
with peak exercise oxygen consumption and New York Heart Association (NYHA) 
functional classification of CHF patients (20, 28).  However, the contribution of elevated 
levels of free radicals to hemodynamic control in patients with CHF at rest and during 
exercise is largely unknown and remains to be elucidated.
Consequently, using rhythmic isometric handgrip exercise and an acute oral AOC, 
this study sought to better characterize the role of free radicals in the regulation of central 
and peripheral hemodynamics at rest and during exercise in patients with CHF.  
Specifically, we hypothesized that, when compared to healthy age-matched controls, 
patients with CHF will exhibit 1) basal evidence of elevated oxidative stress, and that 
during handgrip exercise the patients will reveal, 2) exaggerated central hemodynamic 
responses, particularly in terms of HR and MAP, 3) a significant AOC-induced reduction 
in systemic vascular resistance that will attenuate the increase in MAP, and 4) a similar 
AOC-induced interplay between MAP and peripheral (arm) vascular resistance, such that 




A total of 20 subjects (10 healthy controls and 10 NYHA Class II and III CHF 
patients), were recruited either by flier or in the CHF clinics at the University of Utah and 
the Salt Lake City VA Medical Center. The protocol was approved by these institutions 
and written informed consent was obtained.  Subject characteristics and the 
pharmacological therapy of the CHF patients at the time of the study are reported in 
Tables 5 and 6.  All studies were performed in a thermoneutral environment at least three 
days apart to allow for washout of the oral AOC. Subjects reported to the laboratory in a 
fasted state, and without caffeine or alcohol use for 12 and 24 hrs, respectively.  
Additionally, subjects had not performed any exercise within the past 24 hrs and if 
antioxidants and/or a multivitamin were part of a subject’s daily routine they were asked 
to refrain for at least 3 days prior to testing.
Handgrip Exercise Protocol
Subjects were instrumented with a Finometer (Finapres Medical Systems, 
Amsterdam, The Netherlands) to assess central hemodynamics and then rested supine for 
approximately 20 min prior to baseline resting measurements of MAP, HR, SV, and CO. 
Ultrasound Doppler was used to assess resting brachial artery diameter and blood 
velocity.  While lying in a supine position with the arm resting at 90¶of abduction, with 
the elbow joint extended at heart level, subjects performed a maximal voluntary 
contraction (MVC) (average of three maximal efforts).  Following sufficient rest, 
dynamic handgrip exercise (1 Hz) was performed at three workloads (4-8-12 kg) using a 
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commercially available handgrip dynamometer (TSD121C, Biopack Systems Inc., 
Goleta, CA). The subjects squeezed the dynamometer to the sound (60 beats/min) of a 
digital metronome (Seiko DM70, CA). A computer monitor was positioned so that the 
subjects could observe their force output and make corrections whenever necessary. Each 
exercise-stage lasted 3 min to ensure the attainment of steady-state hemodynamics. 
Central hemodynamics, brachial artery diameter, and blood velocity were assessed 
continuously, but only the steady-state data (last 60 sec) attained during each exercise-
stage were analyzed. 
Central Hemodynamic Assessments
Throughout the entire protocol HR, SV, CO, and MAP signals from the 
Finometer (Finapres Medical Systems BV, Amsterdam, The Netherlands) underwent A/D 
conversion and were simultaneously acquired (200 Hz) using commercially available 
data acquisition software (AcqKnowledge, Biopac Systems). SV was calculated using the 
Modelflow method which includes age, gender, height and weight in its algorithm 
(Beatscope version 1.1; Finapres Medical Systems BV, Amsterdam, The Netherlands) 
(5), and has been documented to accurately track CO during a variety of experimental 
protocols including exercise (8, 9, 14, 42, 47).  CO was then calculated as the product of 
HR and SV.  Systemic vascular resistance was calculated as MAP/CO.
Brachial Artery Assessments
Brachial artery diameter and blood velocities were measured with ultrasound 
Doppler using a General Electric (GE) Logiq 7 ultrasound system (GE Medical Systems, 
50
Milwaukee, WI, USA).  This system was equipped with a linear array transducer 
operating at an imaging frequency of 12-14 MHz, with frequency selected to optimize 
image quality according to vessel depth (18).  Blood velocity was obtained with the same 
transducer with a Doppler frequency of 5 MHz.  An insonation angle of 60º or less was 
utilized and the sample volume was centered within the vessel and maximized according 
to vessel size.  Brachial artery diameters were then analyzed off-line using commercially 
available software (Medical Imaging Applications, LLC, Coralville, IA). Angle-corrected 
and intensity-weighted mean velocities (Vmean) were determined using commercially 
available software (Logic 7).  Using Vmean and arterial diameter, brachial artery blood 
flow was calculated as:  Blood flow = Vmean 	 	_}2 x 60, where blood 
flow is measured in milliliters per min. Peripheral (arm) vascular resistance was 
calculated as MAP/brachial artery blood flow.
Laminar shear stress is believed to be the mechanism that stimulates the vascular 
endothelium and results in subsequent vasodilation of the brachial artery (52).  However, 
as blood viscosity was not measured, shear rate, which can be an adequate surrogate 
measure (35), was calculated using the following equation:   1) = 8½Vmean
(cm/s)/arterial diameter (cm). 
Antioxidant Supplementation
On two separate visits to the laboratory, separated by a minimum of 3 days, 
subjects received either the AOC or placebo in a balanced, single blind design. The 
supplements were administered 90 and 60 min prior to the FMD protocol.  A split dosing 
was used to improve absorbance and distribution of the antioxidants.  The first 
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antioxidant dose included Vitamin E (200 IU), Vitamin C (500 mg), Alpha-lipoic Acid 
(300 mg), and the subsequent dose included Vitamin E (400 IU), Vitamin C (500 mg), 
and Alpha-lipoic Acid (300 mg). The placebo microcrystalline cellulose capsules, that 
were of similar taste, color, and appearance, were also consumed in two equivalently 
timed doses. The efficacy of this AOC to reduce plasma free radical concentration has 
previously been established using ex-vivo spin trapping and electron paramagnetic 
resonance (EPR) spectroscopy (51).
Oxidative Stress and Antioxidant Assays
In both the placebo and antioxidant trials blood samples were obtained from the 
antecubital vein prior to testing (1 hr following ingestion of the second dose of either 
AOC or placebo).  Serum and plasma samples were stored at -80°C until analysis.  Lipid
peroxidation, a marker of oxidative stress was assessed by quantifying thiobarbituric acid 
reactive substances (TBARS) (54) (Bioassays Systems, Hayward, CA).  Antioxidant 
capacity was assessed by determining the ferric reducing ability of plasma (FRAP), using 
the method described by Benzie and Strain (4). Endogenous antioxidant activity, assessed 
by superoxide dismutase (SOD) and catalase (CAT) activity, were assayed in the plasma 
(49) (Cayman Chemical Company, Ann Arbor, MI) and the efficacy of the AOC to 
acutely raise antioxidant levels in the blood was determined by plasma ascorbic acid 
levels (6) (CosmoBio, Carlsbad, CA). A Lipid panel and complete blood count (CBC) 
were performed by standard clinical techniques.
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Statistical Analyses
Ultrasound measurements were performed continuously during rest and exercise, 
though only the last 60 sec of each stage were analyzed, where Vmean was averaged across 
five 12 sec intervals and diameter measurements were evaluated during diastole. 
Statistical analyses were performed using commercially available software (SPSS 17.0, 
Chicago, IL).  Descriptive statistics were performed on all data.  A 2x2 factors 
(intervention and group) repeated measures analysis of variance ANOVA was used to 
determine if the oxidative stress/antioxidant assays and baseline hemodynamic measures 
differed between groups and intervention.  A 2x3 factors (intervention and exercise 
intensity) repeated-measure ANOVA was performed to identify changes in dependent 
variables within groups, drug condition and across exercise intensities.  Independent t-
tests were used to determine differences in subject characteristics. Significant interactions 
were followed up with the appropriate post hoc analyses.  All data are expressed as 
means ± standard error (SE).  Statistical significance was established at P < 0.05.
Results
Oxidative Stress and Antioxidant Capacity 
The AOC significantly elevated plasma ascorbate concentration by ~32% in both 
the CHF patients and controls 2 hrs after the ingestion of the first dose (CHF 14 ± 1 to 21 
± 1 ug/ml; Controls 16 ± 2 to 24 ± 1 ug/ml) (Figure 9A).  The AOC also significantly 
elevated antioxidant capacity, as measured by FRAP, in the control group (PL 1046 ± 42 
to AOC 1164 ± 41 mM/L) while the CHF patients tended to already have greater 
antioxidant capacity than the control group (p = 0.09) (Figure 9B).  TBARS, a marker of 
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oxidative stress, was significantly elevated in the patients with CHF compared to the 
controls (Figure 9C).  While the AOC lowered TBARS by ~56% in the controls (PL 0.88 
± 0.2 to AOC 0.57 ± 0.1 uM), this intervention appeared to have no such effect on the 
patients with CHF.  Catalase activity was not different between the patients with CHF 
and the controls, but was increased in both groups following the AOC ingestion (Figure 
9D).   SOD activity was ~45% higher in the patients with CHF compared to controls and 
was unaltered in either group by the AOC ingestion (Figure 1E.).
Central Hemodynamics
At rest PL MAP was significantly lower in the CHF patients (86 ± 3 mmHg) 
compared to the controls (96 ± 3 mmHg) (p < 0.05) (Figure 10A), but there were no 
differences in HR, SV, or CO (Figure 10B).  During handgrip exercise PL MAP was 
significantly lower in the CHF patients at all workloads compared to controls (Figure 
10A).  In the CHF patients, ingestion of the AOC resulted in lower MAP at rest (PL 86 ± 
3 mmHg, AOC 82 ± 2 mmHg) and throughout all stages of handgrip exercise 
(approximately 5 mmHg at each workload) (Figure 10A).  This reduction in MAP was 
accompanied by nonsignificant increases in HR and SV which resulted in a statistically 
significant increase in CO at all time points following ingestion of the AOC (Figure 
10B).
Peripheral Hemodynamics
The peripheral hemodynamic responses to handgrip exercise are illustrated in 
Figures 10C, and E.  Resting arm blood flows, measured in the brachial artery, were not 
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different between subject groups or treatments (PL CHF 86 ± 16 ml/min, AOC CHF 71 ± 
15 ml/min; PL controls 105 ± 13 ml/min, AOC controls 99 ± 15 ml/min).  During 
handgrip exercise brachial artery blood flow increased with increasing workload, but 
there was no difference in blood flow between groups under any of the conditions (Figure 
10C).  Similarly, there were no significant differences in vascular conductance at rest 
either between groups or as a consequence of ingesting the AOC (PL CHF 0.9 ± 0.1 
ml/min/mmHg, AOC CHF 0.7 ± 0.1 ml/min/mmHg; PL controls 1.1 ± 0.2 
ml/min/mmHg, AOC controls 1.0 ± 0.2 ml/min/mmHg) and this observation held true 
during exercise (Figure 10E). Brachial artery diameters were not different at rest either 
between groups or as a consequence of ingesting the AOC (PL CHF 5.1 ± 0.3 mm, AOC 
CHF  4.9 ± 0.3 mm; PL controls 4.9 ± 0.2 mm, AOC controls 5.0 ± 0.2 mm) and again 
this observation held true during exercise (data not shown). Shear rate increased with 
exercise intensity and was in most cases well related to the change in arterial diameter for 
both the controls (R2 = 0.63 ± 0.13) and CHF patients (R2 = 0.70 ± 0.13) (Figure 11). The 
AOC had no measurable effect on the relationship between shear rate and brachial artery 
diameter in either the patients with CHF or the controls.
Discussion
This study sought to better characterize the role of free radicals in regulating 
central and peripheral hemodynamics at rest and during exercise in patients with CHF 
using an oral AOC and dynamic handgrip exercise.  Oxidative stress was confirmed to be 
significantly elevated in the CHF patients, but increased activity of the endogenous 
antioxidant SOD suggested some degree of compensation. Although the ingestion of the 
AOC further increased antioxidant capacity in both the patients and controls, only in the
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patients with CHF did the AOC result in a significant hemodynamic response both at rest 
and during exercise. Specifically, in terms of central hemodynamics, the AOC resulted in 
a significant reduction in MAP (~5%), an increase in CO (~10%), and a fall in systemic 
vascular resistance (~12%). The peripheral response to the AOC contrasted starkly with 
these changes with arm blood flow tending to fall and peripheral (arm) vascular 
resistance remaining essentially unchanged. Based upon the recognized link between free 
radicals and sympathetic nerve activity in patients with CHF, these data provide evidence 
that in patients with CHF systemic vascular resistance is, at least in part, free radically-
mediated. However, this does not appear to be the result of limb or skeletal muscle-
specific changes in peripheral resistance. This finding has the potential to guide future 
investigations targeting exercise intolerance and disease progression in this population.
Oxidative Stress and Antioxidants in CHF
Oxidative stress occurs when there is an imbalance between free radical 
production and antioxidant defenses. Both human studies and animal models of CHF 
suggest that oxidative stress is elevated in this disease population and the excess free 
radical load has been implicated in many of the structural and functional changes that are 
characteristic of CHF. Elevated levels of whole-body oxidative stress in the current 
patients with CHF was confirmed by an elevation in TBARS, a marker of lipid 
peroxidation, compared to controls (Figure 9C). This is in agreement with prior work by 
Ellis et al. (13) who also documented elevated TBARS in patients with CHF. In terms of 
the endogenous antioxidant defense system in patients with CHF, previous research has 
been quite inconsistent with studies reporting that activity was increased (10), decreased
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(23, 26), or was unchanged (28).  In the present study the patients with CHF exhibited a
~45% greater SOD activity and a tendency for greater catalase activity (Figure 9D and 
E), but this did not achieve statistical significance. SOD is typically considered as the 
first line of defense against accumulating free-radicals and superoxide is the radical that 
is often linked to vascular dysfunction and exaggerated sympathetic nerve activity in 
CHF patients (22, 44). Although previous findings in terms of SOD activity in patients 
with CHF have been inconsistent, the current data indicating increased SOD activity can 
be interpreted as evidence of a compensatory upregulation due to the concomitantly 
greater oxidative stress evident in these patients.
The efficacy of the AOC utilized in the current study has previously been 
documented by the clear reduction in blood born free radicals directly measured by ex-
vivo spin trapping and electron paramagnetic resonance (EPR) spectroscopy (51).
Interestingly, although in the current study the AOC clearly raised antioxidant levels in 
both the patients with CHF and controls (Figure 9A and B), TBARS were only 
significantly decreased (~50%) in the healthy controls. However, this is in agreement 
with the findings of Ellis et al. (13) who reported that only long-term Vitamin C 
supplementation in CHF patients had a significant effect on TBARS, whereas short-term 
Vitamin C infusion had no measurable effect on this footprint of oxidative stress.
Additionally of note, although there was a main effect of the AOC on the assessment of 
antioxidant capacity, as measured by FRAP, post hoc analyses support the qualitative 
assessment (Figure 9B) that this was driven by a change in the control group and not in 
the patients with CHF. This is likely partially explained by the tendency (p=0.09) for the 
patients with CHF to already have a greater antioxidant capacity than the controls prior to 
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ingesting the AOC, making the AOC-induced increase, an even smaller relative 
component of all the antioxidants assessed by the FRAP. Regardless, it is clear from the 
systemic hemodynamic data that the AOC had a clear physiological impact in the patients 
with CHF and not the controls and this was likely due to differences in initial levels of 
free radicals and oxidative stress.
Oxidative Stress and Central Hemodynamics in CHF
It is well accepted that in CHF patients, sympathetic nerve activity is augmented 
at rest (24, 45) and often well related to disease prognosis (2, 7).   During exercise, 
increased group III and IV muscle afferent nerve activity results in the exercise pressor 
response which increases blood pressure, via sympathetic nerve activity, and ultimately 
blood flow to the active skeletal muscle (40).  However, as sympathetic nerve activity is 
greater in patients with CHF than healthy individuals (30, 34) this appears to negatively 
impact exercise tolerance, which is likely a result of excessive peripheral vascular 
resistance (30, 33). Consequently, we hypothesized that in response to rhythmic 
isometric handgrip exercise, CHF patients would exhibit exaggerated central 
hemodynamic responses, particularly in terms of HR and MAP compared to the controls. 
This was not the case, in fact, the CHF patients in the current study had a significantly 
lower MAP at rest (86 ± 3 mmHg) compared to the controls (96 ± 3 mmHg)  and this 
attenuated MAP remained evident at each exercise workload (4, 8, and 12kg) (Figure 
10A).  There were also no differences in resting HR, SV, or CO between the two subject 
groups (Figure 10).  The lower MAP and unremarkable HR data in the CHF patients at 
rest and throughout exercise is in agreement with several prior human studies (1, 38, 39)
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and can likely be attributed to maintaining the patients pharmacological therapy 
throughout the experiment.  However, we chose this approach to both minimize patient 
risk and better understand the challenges these patients face in the “real world,” when 
their disease is optimally pharmacologically controlled.
Several large clinical trials have found that decreasing sympathetic activity in 
CHF patients can actually improve mortality (31, 32) thus, providing an important 
therapeutic target, particularly during exercise when this response has the potential to be 
more exaggerated in CHF patients.  Given the growing evidence supporting the link 
between oxidative stress and CHF, several studies using animal CHF models and an 
intra-arterial infusion of an endogenous antioxidant mimetic (e.g. mimicking the 
enzymatic activity of SOD) have revealed a  reduction in sympathetic nerve activity and 
therefore the exercise pressor response during muscle contraction (22, 48).  As illustrated 
in Figure 10 (A, B, and D), ingestion of the oral AOC by the patients with CHF in the 
current study resulted in significant central hemodynamic changes which were evident 
both at rest and across all levels of handgrip exercise: MAP was significantly reduced (~5
mmHg), slight, but nonsignificant, increases in HR and SV combined to significantly 
increase CO (~0.4 L/min), and systemic vascular resistance fell significantly (~2 
mmHg/L/min) (Figure 10B). These findings are consistent with the reduced blood 
pressure and sympathetic nerve activity documented in the previously discussed CHF 
animal models (22, 48). While in a CHF-induced rabbit model, supplementation with 
beta-carotene, ascorbic acid (Vitamin C), and alpha-tocopherol (Vitamin E), a 
combination of antioxidants somewhat similar to those used in the current study, reduced 
tissue oxidative stress and attenuated the associated cardiac dysfunction, caused beta-
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receptor downregulation, and reduced sympathetic nerve terminal abnormalities (37). Of 
importance, in the current study, we were able to reveal that systemic vascular resistance
in pharmacologically-treated CHF patients is, at least in part, mediated by free-radicals.
This finding provides important mechanistic insight into the exaggerated sympathetic 
nerve activity exhibited by patients with CHF and has the potential to guide future 
investigations related to exercise intolerance and disease progression in this population.
Oxidative Stress and Peripheral Hemodynamics in CHF
Previous research in CHF patients has reported that peripheral blood flow is 
reduced at rest (55) and during exercise (50) contributing to the exercise intolerance that 
is a hallmark characteristic of the disease.  Although there have been considerable 
variations in terms of the extent and potential mechanisms responsible for the attenuated 
peripheral blood flow in patients with CHF due to methodological differences,
exaggerated sympathoexcitation is likely a primary contributor.  We hypothesized that, as 
with the central hemodynamics, during exercise there would be an AOC-induced 
reduction in peripheral (arm) vascular resistance, such that the potentially exaggerated 
MAP response in patients with CHF patients would not occur.  However, in the placebo 
condition, this group of patients with CHF, using the submaximal handgrip exercise 
model, did not respond differently, in terms of peripheral hemodynamics, from the 
controls. In fact, there were no significant differences in peripheral (arm) vascular 
resistance or brachial artery blood flow (Figure 10C and E) at rest or during exercise 
between the patients and controls, with or without the AOC.  Our findings, under the 
placebo condition, are similar to a previous study by Shoemaker et al. (38) who reported 
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a similarly attenuated MAP in patients with CHF and also failed to see a differences
between the CHF patients and controls in terms of forearm blood flow and vascular 
conductance throughout handgrip exercise.
Given the AOC-induced fall in MAP and recognizing Ohms law and how it 
relates to the human vascular system, either arm vascular resistance, brachial artery blood 
flow or both would be expected to fall in this scenario. Although not statistically 
significant, there was such a trend in blood flow following ingestion of the AOC (Figure
10C), but there was no such trend in arm vascular resistance (Figure 10E). Thus, the 
impact of the AOC on peripheral hemodynamics at both rest and exercise are in stark 
contrast to the previously discussed central hemodynamics, revealing that the central 
changes do not appear to be the result of alterations in arm or skeletal muscle-specific 
peripheral resistance. This suggests that free radicals in patients with CHF do not impact 
skeletal muscle sympathetic nerve activity, but have the majority of effect on other 
organs.
Progressive Handgrip and Nitric Oxide-dependent Vasodilation in CHF
Although not a focus of the current study, performance of this work afforded the 
opportunity to examine vascular function in both controls and patients with CHF utilizing 
a novel approach recently championed by our group. Specifically, we have documented 
that as dynamic handgrip exercise elevates shear stress in an intensity-dependent manner 
that results in a corresponding increase in vessel diameter this model appears to provide 
an assessment of brachial artery vasodilatory capacity (53). Additionally, using intra-
arterial NG-monomethyl-L-arginine (L-NMMA) to block endothelial nitric oxide (NO)
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synthase, we identified NO to be a major contributor to shear-induced brachial artery 
vasodilation during progressive handgrip exercise.  Thus, progressive, dynamic handgrip 
exercise, as used in the current study, may be an effective tool for assessing NO 
bioavailability in humans. However, to date, the application of this approach to assessing 
vascular function has been limited to young healthy volunteers.
Therefore to compare and contrast NO mediated vasodilation in the current older 
controls and the patients with CHF, we examined the relationship between the shear rate 
developed during three stages of exercise and the change in brachial artery diameter
(Figure 11). In general, both the older controls and patients with CHF support the strong 
linear relationship between increasing shear rate induced by incremental handgrip 
exercise and the resulting brachial artery vasodilation (Figure 11). Although the 
preponderance of data examining vascular function in patients with CHF suggests that 
this disease is associated with a decrement in flow mediated vasodilation (11, 19) and by 
inference NO bioavailability, this finding has not always been consistent (21, 36). With 
the current approach, there was no significant difference in the slopes of shear rate to 
brachial artery vasodilation relationships between the controls (m = 0.004 ± 0.001) and 
CHF patients (m = 0.004 ± 0.002). However, it is interesting to note that the slope of this 
relationship for both these groups was lower than the slope previously reported in young, 
healthy individuals (m = 0.005 ± 0.001) and far greater than the slope of the young
subjects with NO blockade (m = 0.0007 ± 0.0005). Therefore, using this novel approach
to assess NO-dependent vasodilation, a significant NO-mediated vasodilatory capacity 
was identified in both groups, but there was no discernible difference between the healthy 
controls and the patients with CHF.
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Conclusion
This study has documented that both at rest and during exercise, in patients with 
CHF exhibiting signs of oxidative stress, central and not peripheral hemodynamics are at 
least partially mediated by free radicals. This finding may provide important mechanistic 
insight into the exaggerated sympathetic nerve activity exhibited by patients with CHF 
and has the potential to guide future investigations targeting exercise intolerance and 
disease progression in this population.
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Table 5. Subject characteristics
Controls CHF
Subjects (n) 10 10
Age (yrs) 60 ± 3 62 ± 2
Weight (kg) 82 ± 3 96 ± 5 *
Height (cm) 176 ± 2 178 ± 2
Body mass index (kg/m2) 26 ± 1 30 ± 1 *
Systolic blood pressure (mmHg) 126 ± 4 114 ± 2 *
Diastolic blood pressure (mmHg) 80 ± 2 71 ± 3 *
Glucose (mg/dL) 80 ± 5 134 ± 25
Cholesterol (mg/dL) 187 ± 9 151 ± 17
HDL (mg/dL) 48 ± 2 40 ± 3 *
LDL (mg/dL) 129 ± 9 95 ± 13 *
Triglycerides (mg/dL) 116 ± 16 109 ± 22
Hemoglobin (g/dL) 16 ± 1 15 ± 3 
Hematocrit (%) 47 ± 1 43 ± 2
RBC (M/ uL) 5.4 ± 0.1 4.8 ± 0.2 *
WBC (K/uL) 5.2 ± 0.3 7.7 ± 0.7 *
Mean ± SE; HDL, high density lipoprotein; LDL, low density 
lipoprotein; RBC, red blood cells; WBC, white blood cells. 
(*) Significantly different from control.
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Left Ventricular Ejection fraction (%) 26 ± 3
NYHA Class II 7
NYHA Class III 3
Diabetic (# of all cases) 3/10
Medications:
Beta-blocker (# of all cases) 9/10
ACE-Inhibitor (# of all cases) 6/10
Angiotensin Receptor Blocker 
(# of all cases)
2/10
Statin (# of all cases) 9/10
Diuretic (# of all cases) 7/10
Calcium channel-blocker
(# of all cases)
0/10
Alpha-blocker (# of all cases) 0/10
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Figure 9. Quantitative assessment of oxidative stress and antioxidant markers in healthy 
controls and CHF patients. (A) Plasma ascorbate; (B) Ferric-reducing ability of plasma 
(FRAP); (C) Thiobartituric Acid Reactive Substances (TBARS); (D) Catalase; (E) 
Superoxide dismutase.  Values are means ± SE. (*) Significantly different from Controls; 
(†) Significantly different from PL.
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Figure 10. Central and peripheral responses to handgrip exercise in heart failure (CHF, 
triangle) and control subjects (Con, circle) with placebo (PL, open symbols) and the 
antioxidant cocktail (AOC, closed symbols). Values are mean ± SE for (A) mean arterial 
pressure (MAP), (B) cardiac output (CO), (C) brachial artery blood flow, (D) systemic 
vascular resistance, and (E) arm vascular resistance.  (*) Significant difference between 
the controls and CHF; (†) Significant difference between PL and AOC.
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Figure 11. Individual regression plots illustrating the relationship between changes in 
brachial artery shear rate and the change in brachial artery diameter during 3 stages of 
handgrip exercise in controls (A) and CHF patients (B). There was no significant 
difference between the average slopes (m) of the two groups. The average strength of the 
relationship between shear rate and brachial artery diameter in the controls and CHF 






Vascular function and blood flow regulation are important to understand and 
monitor as they relate to the prevalence of cardiovascular disease (4) and are even more 
germane in patients with CHF and following HTx. Additionally, in light of the 
increasing interest in isolating the physiological and mechanical contributors to the blood 
flow response, especially during exercise (exercise hyperemia) (10), the abnormal 
hemodynamic responses and exercise intolerance common in CHF and HTx patients may 
help to further explain the mechanisms responsible for vessel vasodilation and exercise 
hyperemia in both health and disease (1, 5).  In CHF patients, elevated free radicals have 
been linked to impaired endothelial-dependent vasodilation (7, 8) and exaggerated 
sympathetic nerve activity particularly with exercise (6, 9).  In HTx recipients, the 
development of high levels of oxidative stress has also been associated with endothelial 
dysfunction (2) and the development of cardiac transplant-associated arteriosclerosis (3).
This, coupled with the highly invasive nature of heart transplantation and the effects of 
previous cardiac illness, lends itself to the idea that antioxidant therapy may decrease 
circulating levels of free radicals and may actually improve vascular function and blood 
flow regulation in HTx recipients. Accordingly, vascular function, blood flow regulation, 
and exercise-induced hyperemia were examined in healthy controls, CHF patients, and 
HTx recipients with varied time since surgery with and without oral antioxidant 
supplementation.  
In the first study, we aimed to determine the central and peripheral contributions 
to movement-induced hyperemia in response to passive movement by comparing humans 
with a denervated heart (HTx) to intact controls.  With this approach, we observed a four-
fold reduction in the transient increase in femoral blood volume entering the leg in 
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response to passive limb movement in the HTx recipients compared to controls. This 
attenuated hyperemic response to movement in the HTx recipients was not likely due to 
diminished peripheral vascular function, as measured by brachial artery FMD and RH, 
implicating a differing central hemodynamic response as the source of disparity in leg 
blood flow.  These findings highlight the key role of the reflex increases in HR and the 
associated rise in CO response as an important mechanism which contributes to 
movement-induced hyperemia in humans.
The second study investigated the changes in vascular function and the role of 
oxidative stress from health to the development of CHF, HTx, and beyond.  Utilizing 
FMD to assess endothelium-dependent vascular function across the continuum, we 
documented reduced vasodilatory capacity in CHF patients, which was improved or 
normalized in early HTx recipients, and then an eventual decline in vascular function in 
the HTx recipients that were the furthest time from transplantation (> 14 yrs post-HTx) to 
a level that was comparable to, if not worse than, before transplantation (CHF).  
Interestingly, unlike the other patient groups, the acute ingestion of the AOC was able to 
significantly increase FMD by 55% in these > 14 yrs post-HTx recipients suggesting that 
free radicals, and the associated decrease in NO bioavailability, are largely responsible 
for their  endothelial dysfunction. Somewhat surprisingly, RH, an index of microvascular 
function, was not different across the groups and there was no effect of the AOC, 
highlighting the differing physiology/pathophysiology assessed by FMD and RH.  Also 
of significant importance to the interpretation of these data is the fact that these 
observations across time (e.g., time post-HTx) were not confounded by aging as the 
controls and all patient groups were of similar age.  These findings not only highlight the 
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transient nature of vascular function over the course of CHF development and following 
HTx but also reveals the significant deterioration in endothelium-dependent vasodilation 
in HTx recipients who are one to two decades beyond surgery.  This ultimate decline, as 
with the controls, appears to be a consequence of a free radically-mediated reduction in 
NO bioavailability. 
The third study sought to better characterize the role of free radicals in regulating 
central and peripheral hemodynamics at rest and during exercise in patients with CHF 
using an oral AOC and dynamic handgrip exercise.  Oxidative stress was confirmed to be 
significantly elevated in the CHF patients, but increased activity of the endogenous 
antioxidant SOD suggested some degree of compensation. Although the ingestion of the 
AOC further increased antioxidant capacity in both the patients and controls, only in the 
patients with CHF did the AOC result in a significant hemodynamic response both at rest 
and during exercise. Specifically, in terms of central hemodynamics, the AOC resulted in 
a significant reduction in MAP (~5%), an increase in CO (~10%), and a fall in systemic 
vascular resistance (~12%). The peripheral response to the AOC contrasted starkly with 
these changes with arm blood flow tending to fall and peripheral (arm) vascular 
resistance remaining essentially unchanged. Based upon the recognized link between free 
radicals and sympathetic nerve activity in patients with CHF, these data provide evidence 
that in patients with CHF systemic vascular resistance is, at least in part, free radically-
mediated. However, this does not appear to be the result of limb or skeletal muscle-
specific changes in peripheral resistance. This finding has the potential to guide future 
investigations targeting exercise intolerance and disease progression in this population.
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Chronic heart failure is one of the most common and costly illnesses as it is a 
manifestation of almost every form of cardiac disease.  It is of utmost importance that we 
understand and investigate the physiological ramifications of CHF as well as HTx as this 
invasive surgery is one of the only treatments for the most severe stages of the disease.  
In summary this research has provided significant insight into the cardiovascular 
consequences of CHF and HTx in terms of vascular function and hemodynamic 
regulation. Combined with the potential role of oxidative stress, the conclusions gleaned 
from these studies have broad applications for better understanding human physiology 
with and without cardiovascular disease as well as important therapeutic implications for 
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